Sarepta Therapeutics, Inc.
215 First Street
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD) and CNS. The Company now has 23 programs in development across several therapeutic modalities, including RNA, gene therapy and gene editing.
Sarepta is writing a new play book, one that has the potential to define rare disease drug development.
- We place the patient front and center to everything we do and every decision we make.
- We are a science-driven organization.
- We work with a bias to action.
- We attract employees who want to make a difference and aren't afraid of upsetting the “norm” - we like disrupters.
- We invest heavily in R&D and are pursuing a model where the pathway is defined and the science compelling.
Sarepta's largest employee population is based in Massachusetts with headquarters in Cambridge and a manufacturing and laboratory facility in Andover, with plans to build a gene therapy Research Center of Excellence in Columbus, Ohio. The Company is also establishing its global presence with new offices in Brazil, Ireland, UK, Germany, France, Italy, and the Nordics, with European headquarters in Zug, Switzerland.
Corporate Mission Statement:
Leading the field of precision medicine to forever change the course of rare disease so patients can dream big, live fully and journey far.
Stock Symbol: SRPT
Stock Exchange: NASDAQ
Check out careers with Sarepta here.
World Duchenne Awareness Day (WDAD) at Sarepta Therapeutics
Sarepta raises awareness for Duchenne muscular dystrophy (DMD) on World Duchenne Awareness Day - September 2018
614 articles with Sarepta Therapeutics, Inc.
7/15/2019It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
7/10/2019All three studies found significant slowing of respiratory decline in the patients receiving Exondys 51 and it was consistent across all stages of the disease studied.
As the largest center for biotech startups in the U.S., the Boston/Cambridge, Massachusetts area often acts as a marker for the entire industry. Here’s a look at the Massachusetts M&A deals so far.
Sarepta struck a deal with the Research Institute at Nationwide Children’s Hospital for the gene therapy candidate, calpain 3.
Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with gene therapy leader Sarepta Therapeutics
With the Catalent transaction anticipated to close in 2Q 2019, the combined strengths of each organization will assure best manufacturing assets and unmatched operational excellence in one of the fastest-growing areas of healthcare
Cambridge, Mass.-based Sarepta Therapeutics announced data from its interim analysis of muscle biopsy endpoints of its therapy casimersen for Duchenne muscular dystrophy (DMD). The interim data was strong enough to support a probable New Drug Application (NDA) submission to the U.S. Food and Drug...
Agreement focused on identification of patients with Duchenne muscular dystrophy (DMD)
Companies to Exercise Purchase Option Agreement Following Positive, Preliminary Data in Limb-Girdle Muscular Dystrophy Type 2E Program
As part of the deal, Sarepta picks up five gene therapy candidates to treat distinct types of LGMD. The original deal was inked in May 2018, when the two companies partnered to develop five gene therapy compounds.
History shows just how slow public health officials, the federal government, regulators and pharmaceutical companies were to respond to the emergence of HIV in the 1980s. The reasons are numerous—it was a puzzling viral disease, it first appeared in what was then a largely stigmatized patient pop...
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy
Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as plasmid capacity for future gene therapy programs
Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
-- Golodirsen has been studied for the treatment of exon 53 amenable patients, approximately eight percent of patients with Duchenne --
The idea of throwing Big Pharma under the bus in order to protect innovative biotech companies sparked a robust conversation at the seventh annual Forbes Healthcare Summit.
AcelRx is seeking $40 million to support the launch of Dsuvia and Sarepta eyes $500 million to support clinical research.
Myonexus Therapeutics Announces the Initiation of a Trial for the First-Ever Gene Therapy for Beta-sarcoglycanopathy, Also Known as Limb-Girdle Muscular Dystrophy Type 2E
First-in-human trial of MYO-101 based on promising pre-clinical results offering the first corrective approach for LGMD2E
Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
The American University Washington College of Law and the Food and Drug Law Institute hosted a conference late last week. One of the highlights was a plenary session that featured former commissioners of the U.S. Food and Drug Administration (FDA).
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
Expands Sarepta’s portfolio to as many as 14 gene therapy programs
Sarepta Therapeutics’ experimental gene-therapy treatment for Duchenne muscular dystrophy (DMD) is showing some early signs of promise. Patients who received the therapy are showing increasing signs of a muscle protein that had been missing, the company said.